Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Yang, Hanseul ^a   Kim, Chan ^a   Kim, Min Ju ^b   Schwendener, Reto A ^c   Alitalo, Kari ^d   Heston, Warren ^e   Kim, Injune ^a   Kim, Wun Jae ^b   Koh, Gou Y ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD68 ANTIGEN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER INVASION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; ORTHOTOPIC URINARY BLADDER CANCER; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; BLADDER TUMOR; C3H MOUSE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MACROPHAGE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOLUBILITY; TUMOR CELL LINE;

ADENOVIRIDAE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MACROPHAGES; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOLUBILITY; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 79953790937     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-36     Document Type: Article

References (37)

1. Hussain S, James N. The systemic treatment of advanced and metastatic bladder cancer. The Lancet Oncology 2003, 4:489-497. 10.1016/S1470-2045(03)01168-9, 12901963.
2. Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic Pattern of Bladder Cancer: Correlation With the Characteristics of the Primary Tumor. Am J Roentgen 2011, 196:117.
3. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995, 87:1603-1612. 10.1093/jnci/87.21.1603, 7563203.
4. Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000, 6:4866-4873.
5. Fernandez MI, Bolenz C, Trojan L, Steidler A, Weiss C, Alken P, Grobholz R, Michel MS. Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. Eur Urol 2008, 53:571-578. 10.1016/j.eururo.2007.08.030, 17804149.
6. Saban MR, Towner R, Smith N, Abbott A, Neeman M, Davis CA, Simpson C, Maier J, Memet S, Wu XR, Saban R. Lymphatic vessel density and function in experimental bladder cancer. BMC Cancer 2007, 7:219. 10.1186/1471-2407-7-219, 2241841, 18047671.
7. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953. 10.1038/nature04480, 16355212.
8. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 2008, 3:367-397. 10.1146/annurev.pathmechdis.3.121806.151515, 18039141.
9. He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 2004, 1654:3-12.
10. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007, 109:1010-1017. 10.1182/blood-2006-05-021758, 1785149, 17032920.
11. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002, 2:573-583. 10.1038/nrc863, 12154350.
12. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002, 94:819-825.
13. Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, Pytowski B, Fukumura D, Padera TP, Jain RK. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 2006, 66:8065-8075. 10.1158/0008-5472.CAN-06-1392, 16912183.
14. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 2005, 65:6901-6909. 10.1158/0008-5472.CAN-05-0408, 16061674.
15. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006, 66:2650-2657. 10.1158/0008-5472.CAN-05-1843, 16510584.
16. Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J, Hayashi T, Kanetake H. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res 2006, 12:800-806. 10.1158/1078-0432.CCR-05-1284, 16467091.
17. Suzuki K, Morita T, Tokue A. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol 2005, 12:152-158. 10.1111/j.1442-2042.2005.01010.x, 15733109.
18. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8:618-631. 10.1038/nrc2444, 18633355.
19. Lamagna C, Aurrand-Lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006, 80:705-713. 10.1189/jlb.1105656, 16864600.
20. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612. 10.1158/0008-5472.CAN-05-4005, 16423985.
21. Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi M, Miyazono K. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 2007, 67:10181-10189. 10.1158/0008-5472.CAN-07-2366, 17974958.
22. Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, et al. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res 2008, 68:1100-1109. 10.1158/0008-5472.CAN-07-2572, 18281485.
23. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002, 161:947-956. 10.1016/S0002-9440(10)64255-1, 1867252, 12213723.
24. Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WD. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 2000, 7:844-851. 10.1038/sj.gt.3301157, 10845722.
25. Karpanen T, Egeblad M, Karkkainen M, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001, 61:1786.
26. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005, 65:4739. 10.1158/0008-5472.CAN-04-4576, 15930292.
27. Jeffers MD, O'Dowd GM, Mulcahy H, Stagg M, O'Donoghue DP, Toner M. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. J Pathol 1994, 172:183-187. 10.1002/path.1711720205, 7513353.
28. Cheng L, Montironi R, Davidson D, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Modern Pathology 2009, 22:S70-S95. 10.1038/modpathol.2009.1, 19494855.
29. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001, 7:199-205. 10.1038/84651, 11175851.
30. Cho CH, Koh YJ, Han J, Sung HK, Jong Lee H, Morisada T, Schwendener RA, Brekken RA, Kang G, Oike Y, et al. Angiogenic role of LYVE-1-positive macrophages in adipose tissue. Circ Res 2007, 100:e47-57. 10.1161/01.RES.0000259564.92792.93, 17272806.
31. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 2006, 95:272-281. 10.1038/sj.bjc.6603240, 2360657, 16832418.
32. Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 2008, 216:347-354. 10.1002/jcp.21494, 18481261.
33. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor associated macrophage count in human bladder cancer. International J Urol 2000, 7:263-269.
34. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51. 10.1016/j.cell.2010.03.014, 20371344.
35. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660. 10.1038/nature07083, 18594512.
36. Tvorogov D, Anisimov A, Zheng W, Leppanen VM, Tammela T, Laurinavicius S, Holnthoner W, Helotera H, Holopainen T, Jeltsch M, et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010, 18:630-640. 10.1016/j.ccr.2010.11.001, 21130043.
37. Flechon A, Droz J. Chemotherapy practices and perspectives in invasive bladder cancer. Exp Rev Anticancer Thera 2006, 6:1473-1482.